We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
The upcoming report from McKesson (MCK - Free Report) is expected to reveal quarterly earnings of $10.69 per share, indicating an increase of 8.4% compared to the year-ago period. Analysts forecast revenues of $110.11 billion, representing an increase of 6.8% year over year.
Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenue- Prescription Technology Solutions' should arrive at $1.46 billion. The estimate indicates a change of +6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- Medical-Surgical Solutions' will likely reach $3.04 billion. The estimate points to a change of +3.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Adjusted Operating Profit- Medical-Surgical Solutions' of $261.24 million. The estimate compares to the year-ago value of $249.00 million.
Analysts predict that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $295.09 million. Compared to the current estimate, the company reported $261.00 million in the same quarter of the previous year.
McKesson shares have witnessed a change of +9.1% in the past month, in contrast to the Zacks S&P 500 composite's +0.7% move. With a Zacks Rank #3 (Hold), MCK is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from McKesson (MCK - Free Report) is expected to reveal quarterly earnings of $10.69 per share, indicating an increase of 8.4% compared to the year-ago period. Analysts forecast revenues of $110.11 billion, representing an increase of 6.8% year over year.
Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenue- Prescription Technology Solutions' should arrive at $1.46 billion. The estimate indicates a change of +6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- Medical-Surgical Solutions' will likely reach $3.04 billion. The estimate points to a change of +3.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Adjusted Operating Profit- Medical-Surgical Solutions' of $261.24 million. The estimate compares to the year-ago value of $249.00 million.
Analysts predict that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $295.09 million. Compared to the current estimate, the company reported $261.00 million in the same quarter of the previous year.
View all Key Company Metrics for McKesson here>>>McKesson shares have witnessed a change of +9.1% in the past month, in contrast to the Zacks S&P 500 composite's +0.7% move. With a Zacks Rank #3 (Hold), MCK is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .